Experimental REV-ERB-related small molecule · Fact sheet
SR9011
SR9011 is an experimental compound used in circadian-receptor and metabolic research. Microglial and mouse findings do not establish human fat loss, cognitive benefit or a safe dosing schedule.
What is SR9011?
SR9011 and SR9009 are related but different molecules.
A laboratory probe can have multiple effects; target-associated labels do not establish complete selectivity.
Benefits & claims
Interest includes performance or metabolic effects, but a mechanism, hormone change or lean-mass result does not establish safe improvement in athletic function.
What the evidence supports
- In microglia, SR9011 altered cytokine responses, but also reduced phagocytosis, respiration and ATP production.
- Those mixed cellular effects cannot be simplified to improved brain energy or immunity.
- Mouse metabolic findings are not an established human exercise substitute.
Research areas
- Performance-related biology
- Clinical or preclinical disease research
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for SR9011. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- SR9011 and SR9009 are related but different molecules.
Formulation differences
- A laboratory probe can have multiple effects; target-associated labels do not establish complete selectivity.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Long-term clinically meaningful benefit
- Endocrine, cardiovascular and organ safety
- Identity, exposure and interaction differences outside research settings
Side effects & risks
- Reduced cellular metabolic and phagocytic functions require context-specific investigation.
- Human toxicology, pharmacokinetics and long-term circadian consequences remain unknown.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidenceThe cited evidence includes synthetic-ligand mouse experiments, rat microglial culture and in-vitro metabolism studies. No therapeutic human outcome follows from those designs.
Studies
Mouse circadian and metabolic synthetic-ligand study.
Primary rat microglia; mixed immune and metabolic effects.
In-vitro metabolic characterization of SR9009 and SR9011.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
SR9011 has no FDA-approved therapeutic product. The cited research does not establish an approved performance-enhancement use.
Preclinical evidence; no FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Long-term clinically meaningful benefit
- Endocrine, cardiovascular and organ safety
- Identity, exposure and interaction differences outside research settings
Summary
Mouse metabolic findings are not an established human exercise substitute.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedRegulation of circadian behaviour and metabolism by synthetic REV-ERB agonists.
Mouse circadian and metabolic synthetic-ligand study.
- pubmedThe Effect of Rev-erbα Agonist SR9011 on the Immune Response and Cell Metabolism of Microglia.
Primary rat microglia; mixed immune and metabolic effects.
- pubmedIn Vitro Metabolic Studies of REV-ERB Agonists SR9009 and SR9011.
In-vitro metabolic characterization of SR9009 and SR9011.